Literature DB >> 36112037

Bevacizumab-induced Coagulative Necrosis with Restricted Diffusion.

Amit Agarwal1, Amit Desai1, Vivek Gupta1, Prasanna Vibhute1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 36112037      PMCID： PMC9530776          DOI： 10.1148/rycan.220089

Source DB:  PubMed          Journal:  Radiol Imaging Cancer        ISSN： 2638-616X


× No keyword cloud information.
  4 in total

1.  Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.

Authors:  S Mong; B M Ellingson; P L Nghiemphu; H J Kim; L Mirsadraei; A Lai; W Yong; T M Zaw; T F Cloughesy; W B Pope
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

2.  Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.

Authors:  H S Nguyen; N Milbach; S L Hurrell; E Cochran; J Connelly; J A Bovi; C J Schultz; W M Mueller; S D Rand; K M Schmainda; P S LaViolette
Journal:  AJNR Am J Neuroradiol       Date:  2016-08-04       Impact factor: 3.825

3.  Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria).

Authors:  Nikdokht Farid; Daniela B Almeida-Freitas; Nathan S White; Carrie R McDonald; Joshua M Kuperman; Abdulrahman A Almutairi; Karra A Muller; Scott R VandenBerg; Santosh Kesari; Anders M Dale
Journal:  J Neurooncol       Date:  2014-08-19       Impact factor: 4.130

4.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.

Authors:  Martin H Cohen; Yuan Li Shen; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2009-11-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.